Results 191 to 200 of about 61,117 (342)

Review for "Molecular cloning, characterization, and gene expression behavior of glucocorticoid and mineralocorticoid receptors from the Chinese alligator ( <i>Alligator sinensis</i> )"

, 2020
Mary E. White
openalex   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Salt and aldosterone do not get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone [PDF]

, 2011
Decio Armanini, Lorenzo A. Calò, Cristina Fiore   +2 more
openalex   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]

BMC Ophthalmol
Park JY, Jang Y, Hahn S.
europepmc   +1 more source

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

, 2020
Tadakatsu Nakamura, H. Shimizu, Atsuhiro Kawaguchi   +2 more
openalex   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Mineralocorticoid receptor antagonists for acute myocardial infarction: a systematic review and meta-analysis of randomised controlled trials. [PDF]

Open Heart
Ang SP, Chia JE, Lima BB, Iglesias J, Lee E, Krittanawong C, Alam M, Mukherjee D.   +7 more
europepmc   +1 more source

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone [PDF]

, 2015
Natalia Muñoz‐Durango, Andrea Vecchiola, Luis M González-Gómez, Felipe Simón, Claudia A. Riedel, Carlos Fardella, Alexis M. Kalergis   +6 more
openalex   +1 more source

Emerging methods for subtype differentiation in primary aldosteronism

Journal of Internal Medicine, Volume 299, Issue 2, Page 178-195, February 2026.
Abstract Primary aldosteronism (PA) is a common cause of hypertension. Compared to patients with essential hypertension, untreated PA is associated with a two‐ to fourfold greater risk of cardiovascular disease, renal failure, and death. PA is caused by increased secretion of aldosterone from one adrenal gland in 30% of the patients and both adrenal ...
Oskar Ragnarsson, C. Christofer Juhlin, Tobias Åkerström, Per Dahlqvist, Henrik Falhammar, Per Hellman   +5 more
wiley   +1 more source